Risk Factors for Lymphoma in Patients with Inflammatory Bowel Disease: A Case-control Study

被引:32
作者
Afif, Waqqas [1 ,2 ]
Sandborn, William J. [1 ,3 ]
Faubion, William A. [1 ]
Rahman, Meher [4 ]
Harmsen, Scott W. [5 ]
Zinsmeister, Alan R. [5 ]
Loftus, Edward V., Jr. [1 ]
机构
[1] Mayo Clin, Div Gastroenterol & Hepatol, Rochester, MN 55905 USA
[2] McGill Univ, Div Gastroenterol & Hepatol, Ctr Hlth, Montreal, PQ, Canada
[3] Univ Calif San Diego, Div Gastroenterol & Hepatol, La Jolla, CA 92093 USA
[4] Mayo Clin Hlth Syst, Immanuel St Josephs Specialty Clin, Gastroenterol Sect, Mankato, MN USA
[5] Mayo Clin, Div Biomed Stat & Informat, Rochester, MN 55905 USA
关键词
lymphoma; immunosuppressive; anti-TNF-alpha; EPSTEIN-BARR-VIRUS; CROHNS-DISEASE; LYMPHOPROLIFERATIVE DISORDERS; RHEUMATOID-ARTHRITIS; ULCERATIVE-COLITIS; AZATHIOPRINE; THERAPY; INFLIXIMAB; IMMUNOSUPPRESSION; 6-MERCAPTOPURINE;
D O I
10.1097/MIB.0b013e318281325e
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background:Subgroups of patients with inflammatory bowel disease (IBD) may have an increased risk of developing lymphoma. We sought to identify factors that were associated with lymphoma in patients with IBD.Methods:Cases and controls were identified through a centralized diagnostic index. We identified 80 adult patients with IBD who developed lymphoma between 1980 and 2009. For each case, 2 controls were matched for subtype of IBD, geographic location, and length of follow-up. Conditional logistical regression was used to assess associations between risk factors and the development of lymphoma.Results:Sixty patients were males (75%) versus 77 controls (48%). Median age at index date was 59 years for cases and 42 years for controls. Twenty patients (25%) and 23 controls (14%) were receiving immunosuppressive medications at the index date. Four patients (5%) and 6 controls (4%) were receiving anti-tumor necrosis factor agents at the index date. In multiple variable analysis, age per decade (odds ratio, 1.83; 95% confidence interval, 1.37-2.43), male gender (odds ratio, 4.05; 95% confidence interval, 1.82-9.02) and immunosuppressive exposure at the index date (odds ratio, 4.20; 95% confidence interval, 1.35-13.11) were significantly associated with increased odds of developing lymphoma. Disease severity and use of anti-tumor necrosis factor agents were not independently associated with developing lymphoma. When testing was performed on patients exposed to immunosuppressive or anti-tumor necrosis factor medications, Epstein-Barr virus was identified 75% of the time.Conclusions:In this case-control study, increasing age, male gender, and use of immunosuppressive medications were associated with an increased risk of lymphoma in patients with IBD.
引用
收藏
页码:1384 / 1389
页数:6
相关论文
共 34 条
[1]   Risk of Cancer in Inflammatory Bowel Disease Treated With Azathioprine: A UK Population-Based Case-Control Study [J].
Armstrong, Richard G. ;
West, Joe ;
Card, Timothy R. .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2010, 105 (07) :1604-1609
[2]   Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis [J].
Baecklund, E ;
Iliadou, A ;
Askling, J ;
Ekborn, A ;
Backlin, C ;
Granath, F ;
Catrina, AT ;
Rosenquist, R ;
Feltelius, N ;
Sundström, C ;
Klareskog, L .
ARTHRITIS AND RHEUMATISM, 2006, 54 (03) :692-701
[3]   Disease activity and risk of lymphoma in patients with rheumatoid arthritis:: nested case-control study [J].
Baecklund, E ;
Ekbom, A ;
Sparén, P ;
Feltelius, N ;
Klareskog, L .
BRITISH MEDICAL JOURNAL, 1998, 317 (7152) :180-181
[4]   Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study [J].
Beaugerie, Laurent ;
Brousse, Nicole ;
Bouvier, Anne Marie ;
Colombel, Jean Frederic ;
Lemann, Marc ;
Cosnes, Jacques ;
Hebuterne, Xavier ;
Cortot, Antoine ;
Bouhnik, Yoram ;
Gendre, Jean Pierre ;
Simon, Tabassome ;
Maynadie, Marc ;
Hermine, Olivier ;
Faivre, Jean ;
Carrat, Fabrice .
LANCET, 2009, 374 (9701) :1617-1625
[5]   Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease. [J].
Colombel, Jean Frederic ;
Sandborn, William J. ;
Reinisch, Walter ;
Mantzaris, Gerassimos J. ;
Kornbluth, Asher ;
Rachmilewitz, Daniel ;
Lichtiger, Simon ;
D'Haens, Geert ;
Diamond, Robert H. ;
Broussard, Delma L. ;
Tang, Kezhen L. ;
van der Woude, C. Janneke ;
Rutgeerts, Paul .
NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (15) :1383-1395
[6]   The safety profile of infliximab in patients with Crohn's disease: The Mayo Clinic experience in 500 patients [J].
Colombel, JF ;
Loftus, EV ;
Tremaine, WJ ;
Egan, LJ ;
Harmsen, WS ;
Schleck, CD ;
Zinsmeister, AR ;
Sandborn, WJ .
GASTROENTEROLOGY, 2004, 126 (01) :19-31
[7]   Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease:: an open randomised trial [J].
D'Haens, Geert ;
Baert, Filip ;
van Assche, Gert ;
Caenepeel, Philip ;
Vergauwe, Philippe ;
Tuynman, Hans ;
De Vos, Martine ;
van Deventer, Sander ;
Stitt, Larry ;
Donner, Allan ;
Vermeire, Severine ;
Van De Mierop, Frank J. ;
Coche, Jean-Charles R. ;
van der Woude, Janneke ;
Ochsenkuehn, Thomas ;
van Bodegraven, Ad A. ;
van Hootegem, Philippe P. ;
Lambrecht, Guy L. ;
Mana, Fazia ;
Rutgeerts, Paul ;
Feagan, Brian G. ;
Hommes, Daniel .
LANCET, 2008, 371 (9613) :660-667
[8]   Epstein-Barr virus-positive lymphoma in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine [J].
Dayharsh, GA ;
Loftus, EV ;
Sandborn, WJ ;
Tremaine, WJ ;
Zinsmeister, AR ;
Witzig, TE ;
Macon, WR ;
Burgart, LJ .
GASTROENTEROLOGY, 2002, 122 (01) :72-77
[9]  
Hanauer SB, 2001, AM J GASTROENTEROL, V96, P635
[10]  
HANTO DW, 1981, CANCER RES, V41, P4253